S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
NASDAQ:CPIX

Cumberland Pharmaceuticals (CPIX) Stock Forecast, Price & News

$1.79
+0.01 (+0.56%)
(As of 10/3/2023 ET)
Compare
Today's Range
$1.63
$1.87
50-Day Range
$1.43
$2.30
52-Week Range
$1.43
$2.91
Volume
8,978 shs
Average Volume
21,394 shs
Market Capitalization
$25.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CPIX stock logo

About Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

CPIX Price History

CPIX Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Cumberland gets two new firefighting vehicles
Body found at Lake Cumberland
Man dies after hitting tree Cumberland County
See More Headlines
Receive CPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPIX Company Calendar

Last Earnings
8/08/2023
Today
10/03/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CPIX
CUSIP
23077010
Employees
85
Year Founded
1999

Profitability

Net Income
$-5,570,000.00
Pretax Margin
-4.38%

Debt

Sales & Book Value

Annual Sales
$42.01 million
Cash Flow
$0.45 per share
Book Value
$2.45 per share

Miscellaneous

Free Float
8,325,000
Market Cap
$25.72 million
Optionable
Optionable
Beta
0.24

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. A. J. Kazimi MBA (Age 65)
    Founder, Chairman, Pres & CEO
    Comp: $897.5k
  • Mr. John Michael Hamm (Age 67)
    Chief Financial Officer
    Comp: $231.38k
  • Mr. James Lowrance Herman (Age 68)
    Exec. VP of National Accounts & Chief Compliance Officer
    Comp: $352.65k
  • Ms. Jean W. Marstiller (Age 73)
    Sr. VP of Admin. Services & Corp. Sec.
  • Mr. Chris T. Bitterman (Age 58)
    VP of Sales & Marketing
  • Mr. Adam S. Mostafa (Age 43)
    Managing Director
  • Mr. Todd M. Anthony (Age 62)
    VP of Organizational Devel.
  • Ms. Erin Smith Gull
    Sr. Corp. Relations Associate













CPIX Stock - Frequently Asked Questions

How have CPIX shares performed in 2023?

Cumberland Pharmaceuticals' stock was trading at $2.25 at the beginning of the year. Since then, CPIX stock has decreased by 20.4% and is now trading at $1.79.
View the best growth stocks for 2023 here
.

Are investors shorting Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 21,300 shares, an increase of 13.3% from the August 31st total of 18,800 shares. Based on an average daily trading volume, of 20,500 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.3% of the shares of the company are short sold.
View Cumberland Pharmaceuticals' Short Interest
.

When is Cumberland Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CPIX earnings forecast
.

How were Cumberland Pharmaceuticals' earnings last quarter?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released its quarterly earnings results on Tuesday, August, 8th. The specialty pharmaceutical company reported $0.15 EPS for the quarter. The specialty pharmaceutical company earned $10.89 million during the quarter. Cumberland Pharmaceuticals had a positive trailing twelve-month return on equity of 11.44% and a negative net margin of 4.39%.

What is A. J. Kazimi's approval rating as Cumberland Pharmaceuticals' CEO?

9 employees have rated Cumberland Pharmaceuticals Chief Executive Officer A. J. Kazimi on Glassdoor.com. A. J. Kazimi has an approval rating of 9% among the company's employees. This puts A. J. Kazimi in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cumberland Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), Cerecor (CERC), Xeris Biopharma (XERS).

What is Cumberland Pharmaceuticals' stock symbol?

Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."

How do I buy shares of Cumberland Pharmaceuticals?

Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cumberland Pharmaceuticals' stock price today?

One share of CPIX stock can currently be purchased for approximately $1.79.

How much money does Cumberland Pharmaceuticals make?

Cumberland Pharmaceuticals (NASDAQ:CPIX) has a market capitalization of $25.72 million and generates $42.01 million in revenue each year. The specialty pharmaceutical company earns $-5,570,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How can I contact Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The official website for the company is www.cumberlandpharma.com. The specialty pharmaceutical company can be reached via phone at (615) 255-0068, via email at investors@cumberlandpharma.com, or via fax at 615-255-0094.

This page (NASDAQ:CPIX) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -